Vertex Pharmaceuticals, Inc. (VRTX) Misses Q1 EPS by 11c
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $491.34 --0%
Revenue Growth %: +8.4%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Revenue Growth %: +8.4%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q1 EPS of $0.55, $0.11 worse than the analyst estimate of $0.66. Revenue for the quarter came in at $438.7 million versus the consensus estimate of $473.37 million.
Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New leader board: Citi refreshes AI compute semiconductor picks
- KLA Corporation (KLAC) PT Raised to $325 at Cantor Fitzgerald: Limited EPS Upside
- Rosenblatt Reiterates Buy Rating on Quantum Computing, Inc. (QUBT)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
